TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25424933

Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Intravenous hydration
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Severity of GE
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: RV strain G1WTP[8]WT
Number of subjects: 758
Study: 25425121

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa (0.2 mg/kg, intravenous, every-other-week)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Number of subjects: 11
Study: 25425230

Group type: EXPERIMENTAL
Intervention: Trauma Induced Coagulopathy Clinical Score (TICCS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (patients not needing DCR)
Number of subjects: 82
Study: 25425411

Group type: EXPERIMENTAL
Intervention: Compression Released Stabilized (CRS) socket
Number of subjects: 2

Group type: COMPARATOR
Intervention: Traditional transhumeral (TH) socket
Number of subjects: 2
Study: 25425683

Group type: EXPERIMENTAL
Intervention: Flow cytometric immunophenotyping of bone marrow
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Flow cytometric abnormalities in children with refractory cytopenia
Number of subjects: 81
Study: 25425684

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose dexamethasone
Number of subjects: 0
Study: 25426451

Group type: EXPERIMENTAL
Intervention: Ileal Interposition coupled with Sleeve Gastrectomy (IISG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Diverted Sleeve Gastrectomy (IIDSG)
Number of subjects: 75
Study: 25426701

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Biphasic human insulin 30 (BHI)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH) insulin
Number of subjects: 3
Study: 25426834

Group type: EXPERIMENTAL
Intervention: cAd3-EBO vaccine (2×10^11 viral particles)
Number of subjects: 20
Study: 25427282

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 41
Study: 25427521

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Baseline data comparison between responders and non-responders
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall study results
Number of subjects: 35
Study: 25428504

Group type: EXPERIMENTAL
Intervention: MPDL3280A
Number of subjects: 0
Study: 25428602

Group type: EXPERIMENTAL
Intervention: RESOLUTE zotarolimus-eluting stent (R-ZES)
Number of subjects: 165
Study: 25428650

Group type: EXPERIMENTAL
Intervention: Anti-TNF biologicals (infliximab and adalimumab)
Number of subjects: 0
Study: 25428714

Group type: EXPERIMENTAL
Intervention: Whole blood ZPP
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Erythrocyte ZPP
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Erythrocyte protoporphyrin
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Combination of ZPP with haemoglobin concentration
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Conventional cut off points for whole blood ZPP (>70 μmol/mol haem)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: ZPP
Number of subjects: 470
Study: 25428822

Group type: EXPERIMENTAL
Intervention: Primary endovascular therapy
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Primary endovascular therapy (within 180-270 min)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Primary endovascular therapy (severe strokes)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Endovascular thrombectomy
Number of subjects: 1179
Study: 25429097

Group type: EXPERIMENTAL
Intervention: Short resaturation schedule (15 s)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Long resaturation schedule (90 s)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 47
Study: 25429244

Group type: EXPERIMENTAL
Intervention: High protocol use ICUs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low protocol use ICUs
Number of subjects: 0
Study: 25429521

Group type: EXPERIMENTAL
Intervention: Oral vitamin K antagonists
Number of subjects: 1019
Study: 25429526

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² plus cisplatin 70 mg/m² on day 1 every 3 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 42
Study: 25430934

Group type: EXPERIMENTAL
Intervention: CMT Neuropathy Score (CMTNS)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: CMT Examination Score (CMTES)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Genetic diagnosis
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: CMT subtypes distribution
Number of subjects: 1652
Study: 25430947

Group type: EXPERIMENTAL
Intervention: Intramuscular IFN-β-1a autoinjector
Number of subjects: 232
Study: 25431308

Group type: EXPERIMENTAL
Intervention: ICU
Number of subjects: 282

Group type: COMPARATOR
Intervention: OT
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Difficult airway management techniques in OT
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Difficult airway management techniques in ICU
Number of subjects: 282
Study: 25431439

Group type: EXPERIMENTAL
Intervention: Physiotherapy and activity modification
Number of subjects: 120

Group type: COMPARATOR
Intervention: Arthroscopic surgery
Number of subjects: 120
Study: 25431460

Group type: EXPERIMENTAL
Intervention: Leisure time physical activity (LTPA)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Unsupervised resistance exercise (RE)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Supervised resistance exercise program (REP)
Number of subjects: 236
Study: 25432093

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis implantation
Number of subjects: 0
Study: 25432172

Group type: EXPERIMENTAL
Intervention: Pharmacologic inhibition of Akt
Number of subjects: 0
Study: 25432492

Group type: EXPERIMENTAL
Intervention: Hypocaloric balanced diet (HBD) for 12 weeks
Number of subjects: 44
Study: 25432532

Group type: EXPERIMENTAL
Intervention: Emergency video capsule endoscopy (VCE)
Number of subjects: 20
Study: 25432592

Group type: EXPERIMENTAL
Intervention: Peripheral venous blood lactate (VBL)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Arterial blood lactate (ABL)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Capillary blood lactate (CBL)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mortality at 28 days
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Arterial blood lactate, VBL, and CBL
Number of subjects: 103
Study: 25432718

Group type: EXPERIMENTAL
Intervention: Standardized research-based strategy for HA case management
Number of subjects: 3

Group type: COMPARATOR
Intervention: Regular routine in relation to HA
Number of subjects: 3
Study: 25433216

Group type: EXPERIMENTAL
Intervention: Ty21a+Vi
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ty21a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vi
Number of subjects: 0
Study: 25433628

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis continued until age 4 years (n=45)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Co-trimoxazole prophylaxis discontinued at age 2 years (n=46)
Number of subjects: 203

Group type: COMPARATOR
Intervention: HIV-exposed children who stopped co-trimoxazole at age 4 years
Number of subjects: 203

Group type: COMPARATOR
Intervention: HIV-infected children on continuous co-trimoxazole prophylaxis (n=48)
Number of subjects: 203

Group type: COMPARATOR
Intervention: HIV-unexposed uninfected children (n=100)
Number of subjects: 203
Study: 25433674

Group type: EXPERIMENTAL
Intervention: HEART Camp Intervention (HC) group
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard Care (SC) exercise group
Number of subjects: 246
Study: 25435055

Group type: EXPERIMENTAL
Intervention: Definite incident HPV infection of the anus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Possible HPV infections in the anus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Definite incident HPV infection on the penis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Possible HPV infections on the penis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Definite incident HPV infection in the mouth
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HPV types in the quadrivalent vaccine (anal)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HPV types in the quadrivalent vaccine (penile)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transmission probability from penis to anus
Number of subjects: 200
Study: 25435886

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo/no treatment
Number of subjects: 22
Study: 25436806

Group type: EXPERIMENTAL
Intervention: Crizotinib treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stopping crizotinib
Number of subjects: 32
Study: 25438151

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG) 1×10^10 CFU, orally, twice daily for 28 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Number of subjects: 15
Study: 25439094

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction (executive or memory dysfunction)
Number of subjects: 613

Group type: COMPARATOR
Intervention: No cognitive dysfunction
Number of subjects: 613
Study: 25439363

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol combination (BFC)
Number of subjects: 3043

Group type: COMPARATOR
Intervention: Fluticasone-salmeterol combination (FSC)
Number of subjects: 3043
Study: 25439371

Group type: EXPERIMENTAL
Intervention: Atopy (serum specific IgE positivity)
Number of subjects: 14849
Study: 25439577

Group type: EXPERIMENTAL
Intervention: Erythropoietin in addition to hypothermia
Number of subjects: 24
Study: 25439612

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25439689

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab in follicular lymphoma
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab in marginal zone lymphoma
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab in small lymphocytic lymphoma
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 110
Study: 25439769

Group type: EXPERIMENTAL
Intervention: Routine cervical mediastinoscopy before lung resection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Surgical resection after mediastinoscopy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall evaluation of nodal upstaging
Number of subjects: 90
Study: 25439771

Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair using Valiant Captivia
Number of subjects: 50
Study: 25439791

Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced coronary calcium scanning by CT
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Coronary artery CT angiography
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: DNA methylation
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Whole blood-based transcriptome sequencing
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Unbiased proteomics based on mass spectrometry
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Metabolomics and lipidomics on a mass spectrometry platform
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Primary phenotype analysis
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Additional phenotypic analyses
Number of subjects: 7500
Study: 25439846

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx) with tacrolimus and mychophenolate mofetil (MMF) for 6 months, followed by MMF withdrawal.
Number of subjects: 7
Study: 25441108

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 50 mg b.i.d. (n = 4)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 100 mg b.i.d. (n = 5)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 200 mg b.i.d. (n = 18)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall cohort (n = 27)
Number of subjects: 27
Study: 25441562

Group type: EXPERIMENTAL
Intervention: Arthroscopic shoulder stabilization
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open shoulder stabilization
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 25441679

Group type: EXPERIMENTAL
Intervention: Kidney function characterized by estimated glomerular filtration rate (eGFR) using the abbreviated Modification of Diet in Renal Disease formula.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Multivariable regression adjusting for age, race, log tumor necrosis factor α, hypertension, dyslipidemia, and diabetes.
Number of subjects: 97
Study: 25441726

Group type: EXPERIMENTAL
Intervention: Clinical control suggested in the guidelines
Number of subjects: 93
Study: 25441734

Group type: EXPERIMENTAL
Intervention: Danish Bone Society (DBS-DK)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: UK National Osteoporosis Guideline Group (NOGG-UK)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: US National Osteoporosis Foundation (NOF-US)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Garvan Fracture Risk Calculator
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Q-fracture 2012
Number of subjects: 88

Group type: COMPARATOR
Intervention: Agreement among guidelines
Number of subjects: 88
Study: 25441735

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no infection)
Number of subjects: 41
Study: 25441924

Group type: EXPERIMENTAL
Intervention: Non-invasive screening methods (ADA risk test and body composition measures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive screening methods
Number of subjects: 0
Study: 25442036

Group type: EXPERIMENTAL
Intervention: Contura multilumen balloon (CMLB) breast brachytherapy catheter delivering accelerated partial breast irradiation (APBI) with a total dose of 34 Gy in 10 fractions, delivered twice daily.
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Contura multilumen balloon (CMLB) breast brachytherapy catheter at high-volume centers.
Number of subjects: 342
Study: 25442039

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a dose of 42 Gy/3 fractions for targets ≥5 cm and 26 Gy/1 fraction for targets <5 cm.
Number of subjects: 20
Study: 25442084

Group type: EXPERIMENTAL
Intervention: Prophylactic temporary esophageal stenting after single-stage complete Barrett's excision (CBE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Single-stage complete Barrett's excision (CBE)
Number of subjects: 14
Study: 25442074

Group type: EXPERIMENTAL
Intervention: Genomic microarray analysis using formalin-fixed paraffin-embedded tissue (FFPET)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Genomic microarray analysis using frozen tissue (FZT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CEP3 FISH analysis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CGH detection of -3, +8q, -8p on FFPET and FZT
Number of subjects: 44
Study: 25442689

Group type: EXPERIMENTAL
Intervention: Latrine promotion and construction
Number of subjects: 4586

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 4586
Study: 25442806

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (MNZ) combined with ceftriaxone (CTRX) at doses of 500 mg 3 or 4 times a day/1 or 2 g twice a day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (MNZ) combined with ceftriaxone (CTRX)
Number of subjects: 38
Study: 25444147

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 278

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 278
Study: 25444253

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 581

Group type: COMPARATOR
Intervention: No Doxycycline
Number of subjects: 581
Study: 25444307

Group type: EXPERIMENTAL
Intervention: Nosocomial influenza-like illness (noso-ILI)
Number of subjects: 21519

Group type: COMPARATOR
Intervention: Other wards
Number of subjects: 21519
Study: 25444527

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE)
Number of subjects: 8
Study: 25444566

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 593
Study: 25444722

Group type: EXPERIMENTAL
Intervention: CD20-specific CAR coupled with CD137 and the CD3ζ moiety
Number of subjects: 7
Study: 25444781

Group type: EXPERIMENTAL
Intervention: AS02B
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AS02V
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AS01B
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study: 25445775

Group type: EXPERIMENTAL
Intervention: Previously named object pictures
Number of subjects: 0

Group type: COMPARATOR
Intervention: New object pictures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral experiment with previously named pictures as primes
Number of subjects: 0
Study: 25446240

Group type: EXPERIMENTAL
Intervention: Implant-retained FDPs
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tooth-retained FDPs
Number of subjects: 27
Study: 25446831

Group type: EXPERIMENTAL
Intervention: Two doses of A/Netherlands/219/03 (H7N7) pLAIV (10^7.5 TCID50 intranasally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One dose of A/chicken/British Columbia/CN-6/04 (H7N3) pLAIV (10^7.5 TCID50 intranasally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One 45 μg dose of H7N7 pIIV (intramuscularly)
Number of subjects: 0
Study: 25447610

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22576
Study: 25447728

Group type: EXPERIMENTAL
Intervention: HPV DNA detection
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: HPV type distribution
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Overall HPV prevalence
Number of subjects: 443
Study: 25448409

Group type: EXPERIMENTAL
Intervention: 7 months internet-based guided self-help (INT-GSH)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional guided bibliotherapy (BIB-GSH)
Number of subjects: 156
Study: 25448923

Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurement in patients with GERD (erosive esophagitis or nonerosive but pH-abnormal GERD)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurement in patients with eosinophilic esophagitis
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurement before and after acid suppressive therapy
Number of subjects: 348

Group type: COMPARATOR
Intervention: Mucosal impedance (MI) measurement compared to wireless pH monitoring
Number of subjects: 348
Study: 25449006

Group type: EXPERIMENTAL
Intervention: Two-stage repair (n = 27)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Single-stage repair (n = 32)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Unintentionally staged repair (n = 28)
Number of subjects: 87
Study: 25449219

Group type: EXPERIMENTAL
Intervention: Gestational age ≤25 weeks
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Gestational age 26 or 27 weeks
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Gestational age 28 or 29 weeks
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Gestational age ≥30 weeks
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Infants with GA ≤27 weeks
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Previous exam findings, GA, and PMA
Number of subjects: 1239
Study: 25449569

Group type: COMPARATOR
Intervention: ICRA
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: ICRA + ROMA
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: ROMA + ICRA (for all malignancies)
Number of subjects: 461
Study: 25450031

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily and docetaxel 60 mg/m(2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Everolimus alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Everolimus with docetaxel
Number of subjects: 15
Study: 25450151

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy after cervical dual injection (technetium and patent blue) and systematic pelvic node dissection
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 125
Study: 25451051

Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole 9 mg/kg followed by 8 mg/kg every 12 hours, and oral voriconazole 9 mg/kg (max 350 mg) every 12 hours for patients <50 kg or 6 mg/kg followed by 4 mg/kg every 12 hours and 200 mg oral voriconazole every 12 hours for patients ≥50 kg
Number of subjects: 21
Study: 25451053

Group type: EXPERIMENTAL
Intervention: ABT-450 coadministered with ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABT-450 at highest dose
Number of subjects: 0
Study: 25451055

Group type: EXPERIMENTAL
Intervention: Ombitasvir 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ombitasvir 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ombitasvir 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ombitasvir 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ombitasvir (all doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ombitasvir (doses higher than 5 mg)
Number of subjects: 12
Study: 25451401

Group type: EXPERIMENTAL
Intervention: Unique symptom profiles identified in the STAR*D study
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: Overall depression severity control
Number of subjects: 3703
Study: 25452198

Group type: EXPERIMENTAL
Intervention: OneShot Renal Denervation System
Number of subjects: 50
Study: 25452435

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 5566

Group type: COMPARATOR
Intervention: Control (women without diabetes)
Number of subjects: 5566
Study: 25452445

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) with mandatory immunohistochemistry (IHC)
Number of subjects: 153